Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Stabilization priorities
Airway protection triggers
Inability to protect airway
Persistent vomiting with altered mental status
Breathing targets
Pulse oximetry continuous
Supplemental oxygen to SpO2 90% or higher
Circulation targets
Systolic blood pressure 90 mmHg or higher
Large bore IV access if severe illness
Temperature control
Hypothermia prevention during evacuation
Hyperthermia control during exertion
Glucose rapid check
Point of care glucose for altered mental status
Syndrome recognition
High altitude syndromes
Acute mountain sickness
Headache after recent ascent
Gastrointestinal upset
Fatigue or weakness
Dizziness or lightheadedness
Sleep disturbance
High altitude cerebral edema
Ataxia
Altered mental status
Severe headache
Focal neurologic deficits possible
High altitude pulmonary edema
Dyspnea at rest
Cough
Reduced exercise tolerance
Tachycardia
Hypoxemia out of proportion to altitude
Time critical actions
Immediate escalation triggers
If suspected high altitude cerebral edema, immediate descent
Oxygen if available
Dexamethasone initiation
If suspected high altitude pulmonary edema, immediate descent
Oxygen if available
Nifedipine initiation if oxygen limited
If severe symptoms and descent delayed, portable hyperbaric chamber
Repeat sessions until evacuation feasible
Monitoring
Monitoring bundle
Neurologic trend
Mental status trend
Gait assessment trend
Respiratory trend
SpO2 trend with exertion and rest
Work of breathing trend
Fluid status trend
Oral intake
Urine output
Consultation and activation
Support activation
Mountain rescue activation for HACE or HAPE
Weather and terrain constraints
Helicopter eligibility
ICU capable destination for HACE or HAPE
Transfer planning early
History
Altitude exposure
Altitude timeline
Current altitude
Sleeping altitude
Highest altitude reached
Rate of ascent
Sleeping altitude gain per day
Recent rapid ascent or air travel to altitude
Acclimatization status
Days at intermediate altitude
Prior altitude in last 2 months
Symptom profile
Symptom inventory
Headache characteristics
Onset relative to ascent
Severity progression
Gastrointestinal symptoms
Anorexia
Nausea
Vomiting
Neurologic symptoms
Ataxia
Confusion
Irritability
Somnolence
Respiratory symptoms
Dyspnea at rest
Orthopnea
Cough
Pink frothy sputum possible
Risk factors
Predisposition
Prior AMS or HACE or HAPE
Altitude threshold in past episodes
Medication response in past episodes
Cardiopulmonary disease
Pulmonary hypertension
Congenital heart disease
COPD or asthma baseline control
Exertion and cold exposure
High exertion early after arrival
Cold stress
Medication and substance
Exposures
Sedatives and alcohol
Recent use
Contribution to hypoventilation and sleep disturbance
Prophylaxis used
Acetazolamide
Dexamethasone
Nifedipine
Functional status
Performance change
Exercise tolerance compared with baseline at altitude
Inability to keep pace
Inability to perform simple tasks
Physical Exam
General and vitals
Physiologic severity markers
Pulse oximetry
Resting SpO2
SpO2 drop with minimal exertion
Respiratory rate
Tachypnea
Periodic breathing during sleep history correlation
Heart rate
Tachycardia disproportionate to activity
Temperature
Fever suggests infection rather than isolated altitude illness
Neurologic
Cerebral edema screen
Gait and coordination
Tandem gait inability
Truncal ataxia
Mental status
Disorientation
Inattention
Somnolence
Cranial nerve and focal deficits
Papilledema possible
Focal deficit suggests alternative diagnosis
Respiratory
Pulmonary edema screen
Work of breathing
Accessory muscle use
Inability to speak full sentences
Lung auscultation
Crackles often basilar then diffuse
Wheeze possible
Perfusion
Cyanosis
Cool extremities
Cardiovascular
Strain markers
Jugular venous pressure elevation uncommon in isolated HAPE
Right heart strain signs possible
Murmur history for congenital lesions
PITFALLS
Diagnostic pitfalls
Headache at altitude is not always AMS
Migraine
Dehydration
Carbon monoxide exposure in shelters
Dyspnea at altitude is not always HAPE
Pneumonia
Asthma exacerbation
Pulmonary embolism
Differential Diagnosis
Life threatening alternatives
Neurologic emergencies
Stroke ICD-10 I63
Intracranial hemorrhage ICD-10 I61
CNS infection ICD-10 G00
Hypoglycemia ICD-10 E16.2
Respiratory and cardiovascular emergencies
Pulmonary embolism ICD-10 I26
Pneumonia ICD-10 J18
Acute coronary syndrome ICD-10 I21
Heart failure pulmonary edema ICD-10 I50
Mimics and comorbidities
Common mimics
Dehydration or volume depletion ICD-10 E86
Heat illness ICD-10 T67
Hypothermia ICD-10 T68
Acute gastroenteritis ICD-10 A09
Altitude related other
Other altitude syndromes
High altitude retinal hemorrhage SNOMED CT concept
Subacute mountain sickness chronic hypoxia related polycythemia
Laboratory Tests
Core labs when severe or atypical
Hospital evaluation labs
Basic metabolic panel
Sodium mmol/L for vomiting related hyponatremia
Creatinine for dehydration and acetazolamide safety
Complete blood count
Leukocytosis interpretation caution with stress
Anemia contribution to hypoxemia
Venous blood gas
pH assessment
PCO2 mmHg for hypoventilation or fatigue
Lactate mmol/L
Shock marker
Sepsis consideration
Infectious evaluation when indicated
Infection workup
Blood cultures if febrile and toxic appearance
Respiratory viral testing based on local prevalence
Pitfalls and limitations
Interpretation limits
Normal labs do not exclude HACE or HAPE
Mild leukocytosis can be physiologic at altitude
Diagnostic Tests
Scoring Systems
Symptom based scoring
Lake Louise criteria for acute mountain sickness
Headache required after recent ascent
One or more additional symptoms
Gastrointestinal symptoms
Fatigue or weakness
Dizziness or lightheadedness
Sleep disturbance
Functional impairment grading
Mild reduced activity
Moderate stopped ascent
Severe incapacitated
Clinical severity heuristics
Ataxia at altitude treated as HACE until proven otherwise
Dyspnea at rest at altitude treated as HAPE until proven otherwise
MRI
Neuroimaging role
MRI brain for atypical course or nonresponse
Vasogenic edema patterns possible
Corpus callosum splenium lesions possible
MRI limitations at altitude
Access constraints
Imaging not required prior to descent in suspected HACE
CT
Imaging for complications and mimics
CT head for focal deficit or severe altered mental status
Hemorrhage exclusion
Mass lesion exclusion
Chest imaging for pulmonary syndrome
Chest radiograph for suspected HAPE
Patchy bilateral infiltrates often perihilar
Cardiomegaly typically absent
CT pulmonary angiography for PE concern
Ultrasound (or US)
Point of care applications
Lung ultrasound
Diffuse B lines consistent with interstitial edema
Pleural effusions uncommon in isolated HAPE
Cardiac ultrasound
Right ventricular strain assessment for alternative diagnosis
Left ventricular function assessment for cardiogenic edema
IVC ultrasound
Volume status adjunct
Dehydration not primary driver of AMS
Disposition
Level of care
Admission criteria
High altitude cerebral edema
ICU level care
Continuous neurologic monitoring
High altitude pulmonary edema
ICU or monitored setting
Oxygen requirement beyond minimal
Severe acute mountain sickness
Intractable vomiting
Inability to ambulate
Inability to maintain hydration
Discharge criteria
Safe discharge after improvement
Symptom resolution at rest
Headache resolved or minimal
No ataxia
Stable oxygenation
SpO2 acceptable for altitude and baseline
No progression on observation
Reassuring neurologic trend
Reassuring respiratory trend
Transfer and evacuation
Evacuation triggers
Any suspected HACE
Immediate descent and definitive medical evaluation
HAPE with persistent hypoxemia
Descent and oxygen during transport
Descent not feasible
Portable hyperbaric therapy bridge
Rescue activation
Treatment
Core principles
Definitive therapy
Descent
Minimum 300 m to 1000 m decrease in sleeping altitude
Continued descent until sustained improvement
Oxygen therapy
Target SpO2 90% or higher
Nasal cannula or mask based on availability
Rest
Stop ascent for all symptomatic patients
Avoid exertion until symptoms resolve
Acute mountain sickness
Symptomatic management
Analgesia
Ibuprofen PO 400 mg to 600 mg every 6 to 8 hours as needed
Acetaminophen PO 650 mg to 1000 mg every 6 to 8 hours as needed
Antiemetic
Ondansetron ODT or PO 4 mg to 8 mg every 8 hours as needed
Hydration
Oral fluids guided by thirst
Avoid overhydration and hyponatremia risk
Acetazolamide treatment
Acetazolamide PO 250 mg every 12 hours
Onset of benefit within 12 to 24 hours
Sulfonamide nonantibiotic cross reactivity low but caution
Dexamethasone for moderate to severe AMS
Initiate dexamethasone if severe symptoms or inability to descend
Dexamethasone PO or IM or IV 4 mg every 6 hours
Rebound symptoms possible after stopping without acclimatization
High altitude cerebral edema
Immediate therapy bundle
If suspected HACE, initiate descent immediately
Assisted descent if ataxic
Litter evacuation if unable to walk
Oxygen
High flow if available
Target SpO2 90% or higher
Dexamethasone
Initiate dexamethasone immediately
Dexamethasone IV or IM or PO 8 mg once
Then dexamethasone 4 mg every 6 hours
Continue until symptom resolution and at least 24 hours at lower altitude
Portable hyperbaric chamber if descent delayed
Treatment cycles
Typical session 60 minutes to 90 minutes
Repeat if symptoms recur before evacuation
Adjuncts and cautions
Acetazolamide role limited in established HACE
Primary reliance on descent and dexamethasone
Avoid sedatives
Hypoventilation risk
Mental status masking
High altitude pulmonary edema
Immediate therapy bundle
If suspected HAPE, initiate descent immediately
Minimal exertion strategy
Assisted transport if possible
Oxygen
Highest available flow
Target SpO2 90% or higher
Nifedipine when oxygen limited or severe cases
Initiate nifedipine extended release PO 30 mg every 12 hours
Monitor for hypotension
Avoid immediate release high dose hypotension risk
Portable hyperbaric chamber if descent delayed
Repeat sessions as bridge to evacuation
Other pulmonary vasodilators in selected cases
PDE5 inhibitor prophylaxis or adjunct
Tadalafil PO 10 mg every 12 hours for HAPE prone individuals
Sildenafil PO 50 mg every 8 hours alternative
Inhaled beta agonist prophylaxis selected
Salmeterol inhaled 125 micrograms every 12 hours adjunct when other options limited
Diuretics and antibiotics caveats
Diuretics generally avoided
Intravascular depletion risk
HAPE is noncardiogenic
Antibiotics only if infection suspicion
Fever and purulent sputum
Focal consolidation on imaging
Prevention and acclimatization
Ascent strategy
Sleeping altitude gain limits
Gradual ascent
Rest day every 3 to 4 days at higher altitude
High risk patient strategy
Lower initial sleeping altitude
Conservative itinerary
Acetazolamide prophylaxis
Initiate 24 hours before ascent if possible
Acetazolamide PO 125 mg every 12 hours
Continue for 48 hours after highest sleeping altitude reached
Dexamethasone prophylaxis when acetazolamide not tolerated
Dexamethasone PO 2 mg every 6 hours
Dexamethasone PO 4 mg every 12 hours alternative
HAPE recurrence prophylaxis
Nifedipine extended release PO 30 mg every 12 hours during ascent for known HAPE susceptibility
Tadalafil PO 10 mg every 12 hours alternative
Evidence levels and guideline framing
Evidence statement mapping
Descent is first line for HACE and HAPE
Class I recommendation based on expert consensus
ACEP Level C style consensus grading when applied
Oxygen is first line adjunct for HACE and HAPE
Class I recommendation based on expert consensus
ACEP Level C style consensus grading when applied
Dexamethasone for HACE
Class I recommendation based on guideline consensus
Nifedipine for HAPE when oxygen limited
Class IIa recommendation based on guideline consensus
Special Populations
Pregnancy
Pregnancy considerations
Maternal fetal risk
Hypoxemia risk for fetus
Lower threshold for descent
Medication considerations
Acetazolamide risk benefit discussion
Dexamethasone use for maternal indication when severe illness
Disposition bias
Hospital evaluation for moderate to severe symptoms
Obstetric consultation when viable gestation
Geriatric
Older adult considerations
Comorbidity burden
Cardiac disease mimic risk
Pulmonary disease baseline limitation
Medication adverse effects
Nifedipine hypotension risk higher
Polypharmacy interactions
Disposition bias
Lower threshold for admission
Early imaging for alternative diagnoses
Pediatrics
Pediatric considerations
Presentation differences
Irritability as mental status change
Poor feeding
Weight based dosing
Acetazolamide prophylaxis 2.5 mg/kg per dose every 12 hours
Maximum acetazolamide 125 mg per dose for prophylaxis common practice
Dexamethasone dosing
Dexamethasone 0.15 mg/kg per dose every 6 hours for severe illness
Maximum dexamethasone 4 mg per dose typical
Safety
Early assisted descent for any ataxia or lethargy
Background
Epidemiology
Frequency and patterns
Acute mountain sickness common above 2500 m
Incidence increases with rapid ascent and higher sleeping altitude
High altitude cerebral edema uncommon
Usually progression from severe AMS
High altitude pulmonary edema uncommon
Higher risk with prior HAPE history
Pathophysiology
Mechanisms
Hypobaric hypoxia
Lower inspired oxygen partial pressure
Hyperventilation and respiratory alkalosis
AMS and HACE pathway
Neurohormonal and inflammatory responses
Vasogenic edema contribution
HAPE pathway
Hypoxic pulmonary vasoconstriction
Uneven pulmonary vascular response
High pulmonary artery pressures
Capillary leak noncardiogenic edema
Therapeutic Considerations
Treatment rationale
Descent increases inspired oxygen pressure
Rapid physiologic reversal
Addresses root hypoxia driver
Oxygen increases alveolar oxygen pressure
Decreases hypoxic pulmonary vasoconstriction
Reduces cerebral hypoxia burden
Acetazolamide enhances acclimatization
Carbonic anhydrase inhibition
Metabolic acidosis stimulus for ventilation
Dexamethasone reduces symptoms and edema risk
Anti inflammatory effects
Symptom improvement bridge to descent
Nifedipine reduces pulmonary artery pressure
Pulmonary vasodilation
Improves oxygenation in HAPE
Patient Discharge Instructions
copy discharge instructions
Discharge guidance
Activity and altitude
No further ascent until symptoms fully resolved
Rest day at same altitude after resolution
Medications
Acetazolamide continuation plan if started
Dexamethasone stop plan with caution for rebound
Hydration and sleep
Drink to thirst
Avoid alcohol and sedatives
Return to urgent care or emergency
Worsening headache despite rest and medication
New vomiting or inability to keep fluids down
Any ataxia or difficulty walking straight
Confusion or unusual sleepiness
Shortness of breath at rest
Chest tightness or cough worsening
Blue lips or severe weakness
Follow up
Travel medicine or primary care review before next high altitude trip
HAPE or HACE history flagged for future prophylaxis planning
References
Clinical guidelines and consensus
Key guideline sources
Wilderness Medical Society clinical practice guidelines for prevention and treatment of acute altitude illness
UIAA and ISMM consensus statements on altitude illness recognition and management
Evidence based sources
Foundational evidence and reviews
High altitude cerebral edema and pulmonary edema clinical reviews in peer reviewed emergency and wilderness medicine literature
Acetazolamide randomized trials for AMS prevention
Nifedipine studies for HAPE treatment and prophylaxis
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.